1. S961 Risk of New or Recurrent Cancer After Vedolizumab or Ustekinumab Exposure in Patients With Inflammatory Bowel Disease and Previous Cancer. (October 2021) Authors: Zenger, Cameron; Hong, Simon J.; Pecoriello, Jillian; Pang, Alice S.; Vallely, Margaret; Hudesman, David; Chang, Shannon; Axelrad, Jordan Journal: American journal of gastroenterology Issue: Volume 116:Supplement(2021)ACG Annual Meeting Abstracts 1 Page Start: S460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗